OBJECTIVE: The alpha(2)-Heremans-Schmid glycoprotein (AHSG; fetuin-A in animals) impairs insulin signaling in vitro and in rodents. Whether AHSG is associated with insulin resistance in humans is under investigation. In an animal model of diet-induced obesity that is commonly associated with hepatic steatosis, an increase in Ahsg mRNA expression was observed in the liver. Therefore, we hypothesized that the AHSG plasma protein, which is exclusively secreted by the liver in humans, may not only be associated with insulin resistance but also with fat accumulation in the liver. RESEARCH DESIGN AND METHODS: Data from 106 healthy Caucasians without type 2 diabetes were included in cross-sectional analyses. A subgroup of 47 individuals had data from a longitudinal study. Insulin sensitivity was measured by a euglycemic-hyperinsulinemic clamp, and liver fat was determined by (1)H magnetic resonance spectroscopy. RESULTS: AHSG plasma levels, adjusted for age, sex, and percentage of body fat, were higher in subjects with impaired glucose tolerance compared with subjects with normal glucose tolerance (P = 0.006). AHSG plasma levels were negatively associated with insulin sensitivity (r = -0.22, P = 0.03) in cross-sectional analyses. Moreover, they were positively associated with liver fat (r = 0.27, P = 0.01). In longitudinal analyses, under weight loss, a decrease in liver fat was accompanied by a decrease in AHSG plasma concentrations. Furthermore, high AHSG levels at baseline predicted less increase in insulin sensitivity (P = 0.02). CONCLUSIONS: We found that high AHSG plasma levels are associated with insulin resistance in humans. Moreover, AHSG plasma levels are elevated in subjects with fat accumulation in the liver. This is consistent with a potential role of AHSG as a link between fatty liver and insulin resistance.
OBJECTIVE: The alpha(2)-Heremans-Schmid glycoprotein (AHSG; fetuin-A in animals) impairs insulin signaling in vitro and in rodents. Whether AHSG is associated with insulin resistance in humans is under investigation. In an animal model of diet-induced obesity that is commonly associated with hepatic steatosis, an increase in Ahsg mRNA expression was observed in the liver. Therefore, we hypothesized that the AHSG plasma protein, which is exclusively secreted by the liver in humans, may not only be associated with insulin resistance but also with fat accumulation in the liver. RESEARCH DESIGN AND METHODS: Data from 106 healthy Caucasians without type 2 diabetes were included in cross-sectional analyses. A subgroup of 47 individuals had data from a longitudinal study. Insulin sensitivity was measured by a euglycemic-hyperinsulinemic clamp, and liver fat was determined by (1)H magnetic resonance spectroscopy. RESULTS:AHSG plasma levels, adjusted for age, sex, and percentage of body fat, were higher in subjects with impaired glucose tolerance compared with subjects with normal glucose tolerance (P = 0.006). AHSG plasma levels were negatively associated with insulin sensitivity (r = -0.22, P = 0.03) in cross-sectional analyses. Moreover, they were positively associated with liver fat (r = 0.27, P = 0.01). In longitudinal analyses, under weight loss, a decrease in liver fat was accompanied by a decrease in AHSG plasma concentrations. Furthermore, high AHSG levels at baseline predicted less increase in insulin sensitivity (P = 0.02). CONCLUSIONS: We found that high AHSG plasma levels are associated with insulin resistance in humans. Moreover, AHSG plasma levels are elevated in subjects with fat accumulation in the liver. This is consistent with a potential role of AHSG as a link between fatty liver and insulin resistance.
Authors: Julian A J Jaros; Daniel Martins-de-Souza; Hassan Rahmoune; Emanuel Schwarz; F Markus Leweke; Paul C Guest; Sabine Bahn Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-12-15 Impact factor: 5.270
Authors: T Filardi; F Panimolle; C Tiberti; C Crescioli; A Lenzi; N Pallotta; S Morano Journal: J Endocrinol Invest Date: 2020-04-30 Impact factor: 4.256
Authors: Jessica N Kuzma; Gail Cromer; Derek K Hagman; Kara L Breymeyer; Christian L Roth; Karen E Foster-Schubert; Sarah E Holte; David S Weigle; Mario Kratz Journal: Am J Clin Nutr Date: 2016-06-29 Impact factor: 7.045
Authors: Sulgi Kim; Hanna E Abboud; Madeleine V Pahl; John Tayek; Susan Snyder; James Tamkin; Harry Alcorn; Eli Ipp; Cynthia C Nast; Robert C Elston; Sudha K Iyengar; Sharon G Adler Journal: Clin J Am Soc Nephrol Date: 2010-03-18 Impact factor: 8.237
Authors: Jiankang Liu; Solomon K Musani; Aurelian Bidulescu; J Jeffery Carr; James G Wilson; Herman A Taylor; Caroline S Fox Journal: Atherosclerosis Date: 2012-08-10 Impact factor: 5.162
Authors: N Stefan; A Peter; A Cegan; H Staiger; J Machann; F Schick; C D Claussen; A Fritsche; H-U Häring; E Schleicher Journal: Diabetologia Date: 2008-02-20 Impact factor: 10.122